Time

Hair follicles respond slowly, and a treatment is not fairly tested at six weeks. Our results timeline explains why, and what the research says about reversal sets realistic expectations. Slowed loss counts as a result.

Consistency, dose and route

Missed doses, a low minoxidil strength or a formulation that irritates the scalp (and so gets used less) all look like treatment failure. Switching route, such as from topical to oral minoxidil, is covered below.

The diagnosis

Shedding that started suddenly, or that is diffuse, can be telogen effluvium rather than pattern loss, and the treatments differ. See telogen effluvium versus androgenetic alopecia.

Other contributors

Nutritional deficiencies, thyroid problems and scalp inflammation can sit on top of pattern loss. Our nutritional deficiencies article covers what the evidence supports testing for.

Finasteride primarily inhibits type II 5-alpha reductase, whereas dutasteride inhibits both type I and type II, so it lowers DHT further. In a randomised, active- and placebo-controlled trial of 917 men (Gubelin Harcha et al., 2014), dutasteride 0.5 mg increased hair count and width more than finasteride 1 mg and placebo at 24 weeks. The trial lasted only 24 weeks. In the UK it is prescribed off-label for pattern hair loss, so availability depends on the prescriber. Our direct comparison covers the trials and side-effect picture, and the topical dutasteride and topical finasteride articles cover the lower-exposure routes.

Oral minoxidil is prescribed off-label for hair loss at doses below those typically used for blood pressure, with the dose set by the prescriber. It avoids the need for scalp application, which can make it an option for people who struggle with topical formulations or adherence. Whether switching routes improves results depends on the individual, and oral treatment carries systemic risks that topical treatment does not. Most of the large datasets are observational, and the randomised comparisons with topical minoxidil are fewer, so the safety data below are the best-characterised part.

A retrospective multicentre study of 1,404 patients (about two-thirds women) who took low-dose oral minoxidil for at least three months, at a mean dose of 1.63 mg a day. Adverse events occurred in 20.6%, the commonest being hypertrichosis (15.1%). Lightheadedness (1.7%), fluid retention (1.3%) and tachycardia (0.9%) were uncommon, 1.2% stopped because of systemic effects, and no life-threatening events were reported. It had no control group and did not record comorbidities, so it describes tolerability rather than proving efficacy.

Microneedling is the best-trialled non-drug add-on to minoxidil, though the evidence base is small. It is accessible, but the evidence does not establish an ideal needle depth or home protocol. The trial below used 1.5 mm needles weekly under study conditions, so its results should not be read as a recommendation to reproduce that depth at home. Hygiene, injury risk and the timing of topical applications also matter.

A randomised, evaluator-blinded pilot of 100 men with mild to moderate androgenetic alopecia, comparing 5% minoxidil twice daily with the same minoxidil plus weekly 1.5 mm microneedling. At week 12 the mean change in hair count in a marked 1 cm² area was 91.4 with the combination and 22.2 with minoxidil alone, and patients' own ratings favoured the combination. It was a pilot with a short follow-up, so it supports microneedling as an adjunct to minoxidil rather than a standalone treatment.

Red and near-infrared light devices (caps, combs, helmets) are FDA-cleared rather than FDA-approved, a lower regulatory bar than for drugs, and results depend on the device and its dose of light. The research behind it is real but varied. A 2017 review (below) identified five randomised controlled trials in male or female pattern hair loss. Later meta-analyses, in 2019 and 2025, reported greater hair density than sham or placebo, although both reported high heterogeneity between studies, so device design, protocol and quality still matter.

An evidence-based review that found 21 relevant studies (two in vitro, seven in animals and twelve clinical), of which five were randomised controlled trials in male or female pattern hair loss. It is a review of a small, varied literature, which is why device choice and consistent use matter more than the category name.

A comparison of finasteride with minoxidil, and with 2% ketoconazole shampoo, found the finasteride-plus-ketoconazole group performing on par with finasteride plus minoxidil, but that arm had only 10 patients. A systematic review found just five human studies, with 318 participants in total, so the evidence is thin. It is a wash-off product, and scalp inflammation can itself drive shedding, which may be part of why some people benefit.

The best-controlled trial tested it as an add-on. In 66 women with female pattern hair loss, cetirizine plus minoxidil gave a greater increase in hair shaft thickness and hairs per follicular unit than placebo plus minoxidil over 24 weeks. A 2025 trial in 80 men delivered cetirizine through microneedling and reported more hair density gain than microneedling with saline over eight weeks, so those results apply to that delivery method rather than to an ordinary leave-on product. Head to head, cetirizine alone did worse than minoxidil, so the case is for adding it, not replacing anything.

An early pharmacokinetic study (Ferry et al., 1990) found that tretinoin increased the absorption of minoxidil from an aqueous solution, which is the usual reason the two are paired. Increased absorption does not by itself prove better hair-growth outcomes, and tretinoin's independent effect on hair is less certain. Scalp irritation can also complicate treatment, and it adds a confounder if tretinoin is started at the same time as other changes.

A double-blind, placebo-controlled trial in 40 women with androgenetic or diffuse hair loss, using a 0.1% solution for six months, found a statistically significant rise in occipital anagen rate over placebo. Most other studies are open-label, and none shows it matching established treatments.

A 2007 study kept human hair follicles in culture and reported longer hair shaft elongation with the copper peptide, along with signs of increased follicle cell proliferation. That is organ-culture work, which shows activity in the follicle itself rather than results on a living scalp. Our AHK-Cu versus minoxidil and copper peptides with minoxidil articles cover how it fits beside the options above, and the AmpleLab AHK-Cu Hair & Scalp Serum page has the formulation.

The proposal is that 2dDR raises VEGF and supports the blood supply around the follicle, a mechanism shown in wound-healing and angiogenesis models. A 2024 study reported hair regrowth in a testosterone-induced alopecia mouse model, using a sustained-release hydrogel at 0.394% w/w, which is a different format from a leave-on serum. Our 2dDR versus minoxidil and 2dDR with minoxidil articles go through the comparison, and the AmpleLab 2dDR Hair Serum page has the formulation.

A peptide that blocks the CXXC5 and Dishevelled interaction, releasing a brake on Wnt/beta-catenin signalling. A 2017 paper reported hair regrowth with a competing peptide in mice, and that CXXC5 is raised in human balding scalps. The Wnt route is separate from the androgen and vascular approaches above, which is part of its appeal, and our CXXC5 guide explains the mechanism. The AmpleLab PTD-DBM Hair & Scalp Serum page lists the formulation.

What can I add if finasteride and minoxidil are not working?

First check that enough time has passed and the diagnosis is right. The options with human trial data are a switch to dutasteride, low-dose oral minoxidil in place of topical, weekly microneedling alongside minoxidil, and low-level light therapy. Ketoconazole shampoo, topical cetirizine, tretinoin and melatonin have smaller human datasets. Copper peptides, 2dDR and PTD-DBM act on separate pathways and are at an earlier research stage.

Is dutasteride better than finasteride for hair loss?

In the randomised trials we reviewed, dutasteride 0.5 mg increased hair count and width more than finasteride 1 mg at 24 weeks, which fits its broader inhibition of 5-alpha reductase. It is prescribed off-label for hair loss in the UK, and trials have reported broadly comparable rates of several adverse effects, particularly sexual adverse effects, but the evidence does not establish that the two medicines are identical in safety. Dutasteride also stays in the body much longer, so the choice belongs with a prescriber.

Is microneedling worth adding to minoxidil?

There is controlled evidence for it, but not much. In a 100-man randomised pilot, weekly microneedling plus 5% minoxidil produced a mean hair count change of 91.4 at 12 weeks against 22.2 for minoxidil alone. It was a pilot with a short follow-up, so it supports microneedling as an adjunct rather than a standalone treatment.

Is low-dose oral minoxidil safe?

In a retrospective study of 1,404 patients, adverse events occurred in 20.6%, mostly hypertrichosis (15.1%), with fluid retention in 1.3%, tachycardia in 0.9% and no life-threatening events. It is prescribed off-label, a baseline cardiovascular assessment is sensible, and it should be started and adjusted by a doctor.

Where do copper peptides, 2dDR and PTD-DBM fit?

They act on pathways separate from finasteride and minoxidil: AHK-Cu on follicle cell signalling, 2dDR on blood supply and PTD-DBM on the Wnt pathway. The research is at an earlier stage. AHK-Cu was studied in human follicle culture, and 2dDR and the CXXC5 approach behind PTD-DBM in mice, with no published human hair trials yet. They are generally considered as additions once the core treatment is in place. AmpleLab makes serums containing all three.

Can I add several things at once?

You can, but you will not know which one is helping or irritating. Changing one thing at a time, with monthly photographs and at least several months per change, gives a clearer answer, and a clinician can advise on combining prescription treatments.

How long should I wait before deciding an addition has failed?

Hair responds over months rather than weeks, so a few weeks is too short. The trials above measured at 12 to 24 weeks, and regrowth can continue beyond that, so judging over at least six months is reasonable, while stopping at once if a product irritates the scalp.